Plague - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 67 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Plague - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Plague - Pipeline Review, H1 2015', provides an overview of the Plague's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Plague, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Plague and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Plague
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Plague and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Plague products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Plague pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons To Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Plague
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Plague pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Plague Overview 8
Therapeutics Development 9
Pipeline Products for Plague - Overview 9
Pipeline Products for Plague - Comparative Analysis 10
Plague - Therapeutics under Development by Companies 11
Plague - Therapeutics under Investigation by Universities/Institutes 12
Plague - Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Unknown Stage Products 15
Plague - Products under Development by Companies 16
Plague - Products under Investigation by Universities/Institutes 17
Plague - Companies Involved in Therapeutics Development 18
Aradigm Corporation 18
Cellceutix Corporation 19
Grifols, S.A. 20
iBio, Inc. 21
Mucosis B.V. 22
Summit Corporation plc 23
Syntiron LLC 24
Tetraphase Pharmaceuticals Inc. 25
Plague - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Combination Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
anthrax + plague vaccine - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
ARD-3100 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
ciprofloxacin hydrochloride - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
plague vaccine - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
plague vaccine - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
plague vaccine - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
plague vaccine - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
plague vaccine - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
plague vaccine - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
plague vaccine - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
plague vaccine - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
PMX-30016 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
pneumonic plaque vaccine - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Small Molecules to Inhibit Yoph Protein Tyrosine Phosphatase for Plague - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
SMT-15000 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
TP-271 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
yersinia pestis vaccine - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Yersinia pestis vaccine - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Plague - Recent Pipeline Updates 57
Plague - Dormant Projects 61
Plague - Discontinued Products 62
Plague - Product Development Milestones 63
Featured News & Press Releases 63
Nov 19, 2012: UK Scientists Report On Efficacy Of Aradigm's Lipoquin Against Pneumonic Plague 63
Jun 05, 2008: Computer Sciences Corporation's DynPort Vaccine Company To Continue Plague Vaccine Development 64
Nov 18, 2005: Computer Sciences Corporation's DynPort Vaccine Company Reaches Milestone In Plague Vaccine Clinical Trial 64
May 17, 2005: Wake Forest Scientists Find New Combination Vaccine Effective Against Plague 65
Jan 10, 2005: Computer Sciences Corporation's DynPort Vaccine Company Enters Clinical Trial For Plague Vaccine Candidate 65
Appendix 66
Methodology 66
Coverage 66
Secondary Research 66
Primary Research 66
Expert Panel Validation 66
Contact Us 66
Disclaimer 67

List of Tables
Number of Products under Development for Plague, H1 2015 9
Number of Products under Development for Plague - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Number of Products under Investigation by Universities/Institutes, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 13
Comparative Analysis by Early Stage Development, H1 2015 14
Comparative Analysis by Unknown Stage Development, H1 2015 15
Products under Development by Companies, H1 2015 16
Products under Investigation by Universities/Institutes, H1 2015 17
Plague - Pipeline by Aradigm Corporation, H1 2015 18
Plague - Pipeline by Cellceutix Corporation, H1 2015 19
Plague - Pipeline by Grifols, S.A., H1 2015 20
Plague - Pipeline by iBio, Inc., H1 2015 21
Plague - Pipeline by Mucosis B.V., H1 2015 22
Plague - Pipeline by Summit Corporation plc, H1 2015 23
Plague - Pipeline by Syntiron LLC, H1 2015 24
Plague - Pipeline by Tetraphase Pharmaceuticals Inc., H1 2015 25
Assessment by Monotherapy Products, H1 2015 26
Assessment by Combination Products, H1 2015 27
Number of Products by Stage and Target, H1 2015 29
Number of Products by Stage and Mechanism of Action, H1 2015 31
Number of Products by Stage and Route of Administration, H1 2015 33
Number of Products by Stage and Molecule Type, H1 2015 35
Plague Therapeutics - Recent Pipeline Updates, H1 2015 57
Plague - Dormant Projects, H1 2015 61
Plague - Discontinued Products, H1 2015 62